Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportEarly Phase (Phase 0 or I) human studies

Impact of Pre-Administration of Anti-IGF-1R Antibody FPI 1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In] FPI 1547 in Patients with Solid Tumors

Andrew Scott, Fred Saad, Daniel Juneau, Michael Brown, Ian Kirkwood, Michelle Nottage, John Rhoden, Julia Kazakin, Joanne Schindler, Nicholas Baca, Richard Sparks, James OLeary and Eric Burak
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 2275;
Andrew Scott
1Austin Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred Saad
2Division of Urology, Centre hospitalier de l’Université de Montréal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Juneau
3Université de Montréal, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Brown
4Centre for Cancer Biology SA Pathology and University of South Australia, Adelaide SA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Kirkwood
5Royal Adelaide Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Nottage
5Royal Adelaide Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Rhoden
6Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Kazakin
7Fusion Pharmaceuticals Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanne Schindler
6Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Baca
8CDE Dosimetry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Sparks
9CDE Dosimetry Services, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James OLeary
6Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Burak
6Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Figures & Data

Figures

  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Pre-Administration of Anti-IGF-1R Antibody FPI 1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In] FPI 1547 in Patients with Solid Tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Impact of Pre-Administration of Anti-IGF-1R Antibody FPI 1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In] FPI 1547 in Patients with Solid Tumors
Andrew Scott, Fred Saad, Daniel Juneau, Michael Brown, Ian Kirkwood, Michelle Nottage, John Rhoden, Julia Kazakin, Joanne Schindler, Nicholas Baca, Richard Sparks, James OLeary, Eric Burak
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2275;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of Pre-Administration of Anti-IGF-1R Antibody FPI 1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In] FPI 1547 in Patients with Solid Tumors
Andrew Scott, Fred Saad, Daniel Juneau, Michael Brown, Ian Kirkwood, Michelle Nottage, John Rhoden, Julia Kazakin, Joanne Schindler, Nicholas Baca, Richard Sparks, James OLeary, Eric Burak
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2275;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Features of 18F-NOTA-FAPI-04 PET/CT for predicting pathological response to neoadjuvant chemoradiotherapy in esophageal cancer
  • Prospective Comparison of mpMRI and 18F-FMAU PET/CT in Image-Guided Prostate Biopsy for Detection of Cancer: Preliminary Results
  • Early detection of radiation-induced myocardial damage using [18F]AlF-NOTA-FAPI PET/CT imaging
Show more Early Phase (Phase 0 or I) human studies

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire